BMJ Open Allostatic load as predictor of mortality: a cohort study from Lolland-Falster, Denmark

Neda Esmailzadeh Bruun-Rasmussen ⁽ⁱ⁾, ¹ George Napolitano,² Christian Christiansen,³ Stig Egil Bojesen,⁴ Christina Ellervik ⁽ⁱ⁾, ^{5,6} Randi Jepsen,¹ Knud Rasmussen,⁵ Elsebeth Lynge¹

ABSTRACT

Objectives The purposes of the present study were to determine the association between (1) 10 individual biomarkers and all-cause mortality; and between (2) allostatic load (AL), across three physiological systems (cardiovascular, inflammatory, metabolic) and all-cause mortality.

Design Prospective cohort study.

Setting We used data from the Lolland-Falster Health Study undertaken in Denmark in 2016–2020 and used data on systolic blood pressure (SBP) and diastolic blood pressure (DBP), pulse rate (PR), waist–hip ratio (WHR) and levels of low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), triglycerides, glycated haemoglobin A1c (HbA1c), C-reactive protein (CRP) and serum albumin. All biomarkers were divided into quartiles with high-risk values defined as those in the highest (PR, WHR, triglycerides, HbA1c, CRP) or lowest (HDL-c, albumin) quartile, or a combination hereof (LDL-c, SBP, DBP). The 10 biomarkers were combined into a summary measure of AL index. Participants were followedup for death for an average of 2.6 years.

Participants We examined a total of 13 725 individuals aged 18+ years.

Primary outcome measure Cox proportional hazard regression (HR) analysis were performed to examine the association between AL index and mortality in men and women.

Results All-cause mortality increased with increasing AL index. With low AL index as reference, the HR was 1.33 (95% CI: 0.89 to 1.98) for mid AL, and HR 2.37 (95% CI: 1.58 to 3.54) for high AL.

Conclusions Elevated physiological burden measured by mid and high AL index was associated with a steeper increase of mortality than individual biomarkers.

INTRODUCTION

Biological markers (biomarkers) were originally defined as 'cellular, biochemical or molecular alterations that are measurable in biological media such as cells, human tissues or fluids'.¹ Later the definition was extended to include 'indicators of normal biological processes, pathogenic processes and pharmacological responses to therapeutic interventions'.² In clinical settings, measurement

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ Analysis based on a large population-based health study.
- ⇒ Complete follow-up for death via linkage with Danish Civil Registration System.
- \Rightarrow Biomarkers from only one point in time.
- ⇒ No biomarker from neuroendocrine system available.

of biomarkers in blood samples is used to detect and diagnose medical conditions. Biomarkers as independent predictors of allcause mortality are therefore of considerable clinical and research interest;³ dyslipidaemia including high levels of triglycerides and lowdensity lipoprotein cholesterol (LDL-c), and low levels of high-density lipoprotein cholesterol (HDL-c), have been reported to be independent risk factors for all-cause mortality.4-6 Lower levels of albumin⁷ and higher levels of C-reactive protein (CRP),8 and glycated haemoglobin A1c (HbA1c)⁹ have likewise been linked to mortality. Also, there is some evidence that the relationship between some of these biomarkers and all-cause mortality varies across sex and age groups.^{10 11}

The concept of allostatic load (AL) refers to the 'wear and tear' of the body resulting from repeated stimulation of stress responses via the hypothalamic-pituitary-adrenal axis and the sympathetic-adrenal-medullary system.¹² As a latent variable, AL cannot be directly measured but it can be estimated using an AL index, which is composite of biomarkers from multiple organ systems integrated into a single score. The first AL developed by Seeman et al in 1997 included 10 biomarkers monitoring various physiological systems.¹³ However, the type and number of biomarkers used in published studies have ranged from 6 to 24.¹⁴ The most frequently used Al construct, originally proposed by Gruenewald *et al* in 2012, 15

To cite: Bruun-Rasmussen NE, Napolitano G, Christiansen C, *et al.* Allostatic load as predictor of mortality: a cohort study from Lolland-Falster, Denmark. *BMJ Open* 2022;**12**:e057136. doi:10.1136/ bmjopen-2021-057136

Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (http://dx.doi.org/10.1136/ bmjopen-2021-057136).

Received 06 September 2021 Accepted 09 May 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Centre for Epidemiological Research, Nykobing Falster Hospital, Nykobing, Denmark ²Department of Public Health. University of Copenhagen, Copenhagen, Denmark ³Department of Internal Medicine, Nykobing Falster Hospital, Nykobing, Denmark ⁴Department of Clinical Biochemistry, Herlev Hospital, Herlev, Denmark ⁵Department of Data and **Development Support, Region** Sjaelland, Soro, Denmark ⁶Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

Correspondence to

Dr Neda Esmailzadeh Bruun-Rasmussen; neebruun@gmail.com includes 24 biomarkers. It has been suggested that in the calculation of AL, the threshold of risk for each biomarker should be obtained by the quartiles or quintiles of the values of the biomarker.¹⁶ AL has been reported to be a better predictor of mortality than individual biomarkers, however, there are still gaps in the understanding of the associations.^{17 18} AL has been suggested also as a tool for allocation of nursing resources.¹⁹

This study provides data from the Lolland-Falster Health Study (LOFUS),²⁰ a population-based survey undertaken in 2016–2020 in Lolland-Falster, a rural–provincial region in Denmark with a life expectancy much below the national average,²¹ and with health problems reported more frequently than in the rest of the country.²² Using the LOFUS data, the purposes of the present study were (1) to determine the association between 10 individual biomarkers and all-cause mortality; and (2) to examine the association between AL, across three physiological systems (cardiovascular, inflammatory, metabolic system) and all-cause mortality. The hypothesis is that AL can be used as an informative tool in predicting future risk of death in the general adult population.

METHODS

Study population

We undertook a prospective cohort study of participants from LOFUS; a household-based population study with data collected between February 2016 and February 2020. Persons aged 18 years and above were randomly sampled from the Danish Civil Registration System and invited to participate together with the rest of their households. Participation required informed consent. A detailed description of the study protocol²⁰ and information on the socioeconomic determinants of participation²³ have been published previously. Persons below 18 years, and pregnant women were excluded from the present study.

Patient and public involvement

Patients were not actively involved in any stage of the present study. Once the paper has been published in the international literature, the key results will be reported also in the local press.

Self-reported data

From questionnaires, we used data on smoking (never, former, current), and presence of chronic conditions (cardiovascular disease, diabetes, cancer) at the time of participation in LOFUS.

Biomarkers

Non-fasting blood samples were collected in vacutainer blood collection tubes (Becton, Dickinson and Company; Franklin Lakes, New Jersey, USA) and kept at room temperature until same day analysis at the Department of Clinical Biochemistry at Nykøbing Falster Hospital, accredited by the International Organization for Standardization 15189. We used data on HDL-c, LDL-c, triglycerides, albumin, CRP and HbA1c. LDL-c was calculated by using Friedewald formula²⁴ when the plasma triglyceride concentration was below 4.5 mmol/L. Systolic (SBP) and diastolic (DBP) blood pressure were based on three consecutive digital measurements on the upper left arm (apparatus type Welch Allyn Connex proBPO 3400). The mean values of the second and third measurement were used in this study (only one measurement was used if the other was missing). Waist-hip ratio (WHR) was calculated by waist-circumference divided by hip circumference. Body mass index (BMI) was defined as weight in kilograms divided by height in metres squared (kg/m²).

In the calculation of AL, biomarkers are most often dichotomised into low and high values based on either a percentile or a predetermined cut-off value.¹⁶ However, before doing so, we mapped for each biomarker the association between level of the marker and all-cause mortality, see Method below. For most biomarkers the association was monotonic (see online supplemental figure 1). These biomarkers were then dichotomised according to the sex-specific and age-specific quartiles. For age, we dichotomised at age 60. Some previous studies focused on AL in people aged 60 and above^{25 26} and we intuitively found it reasonable to distinguish in the same way between 'young' and 'old' people in our data; age 60 was furthermore the median age of our study population; and with this age-dichotomisation we avoided violations of the model assumption in the statistical analysis. We dichotomised biomarkers with high-risk values defined as those in the highest quartile of the sexspecific and age-specific distribution, except for HDL-c and albumin, where the lowest quartile was the high-risk value. For LDL-c, SBP and DBP the associations were U-shaped, and the high-risk values for these biomarkers were therefore defined as including both the lower and the upper quartiles (see online supplemental table 1). For biomarkers with U-shaped associations, we tested out also using octiles as cut-off points. However, this resulted in some violations of the model assumptions in the statistical analysis, and for SBP the upper octile cut-off was from a clinical point of view very high. On this basis we used the quartile cut-offs also for the biomarkers with the U-shaped association. For all biomarkers, the highest and lowest quartile of risk scores were either lower or similar to clinical cut-points.²⁷⁻³¹

BMI was divided into underweight (BMI less than 18.5) normal (BMI 18.5–24.9), overweight (BMI 25.0–29.9) or obese (BMI 30.0 or greater); reported diseases into either present or not; and smoking status into never, former or current.

Allostatic load scores

The AL scores were computed using biomarkers from: the cardiovascular system (CVS) (SBP, DBP and pulse rate (PR)); the metabolic system (MS) (LDL-c, triglycerides, HDL-c, WHR, HbA1c); and the inflammatory system (IS) (CRP, serum albumin). Each system-specific AL score was then defined as the number of biomarkers with a high-risk value, hence as an integer value between 0 and 3 for the CVS, 0 and 5 for the MS and 0 and 2 for IS. The AL index was defined as the sum of all scores and divided in three groups based on tertiles contrasting individuals with (AL: 0–2), mid (AL: 3–4) and high (AL: 5–10). Note that, all biomarkers were given equal weight in accordance with previous studies.¹⁶¹⁸

All-cause mortality

LOFUS participants were followed-up for death with data obtained from the Danish Civil Registration System on 26 February 2021.

Data management and statistical analyses

Observations with missing values in any of the variables were excluded from the analyses (1989 out of 15 714, ie, 12.6%, see online supplemental table 2). Values below the lower limit of detection were replaced with random numbers sampled with replacement from the set $\{k \times 10 \land (-n), k = 1, \dots, L\}$, where n is the variable-specific number of decimals reported in the data and $L \times 10 \land (-n)$ the limit of detection (see online supplemental table 3).

Participants were followed-up from date of participation in the LOFUS study until date of death or end of follow-up on 26 February 2021, whichever came first. In order to define the biomarkers' high-risk values, we first studied the association between levels of each individual biomarker and mortality, allowing for possible non-linear relations. This analysis was carried out via Cox proportional-hazard models with biomarker levels as continuous covariates, modelled with natural cubic splines with 2 df (except for LDL-c, where 3 df were used), and further adjusting for sex and age. By graphical inspection, a U-shaped association was found for LDL-c, SBP and DBP (see online supplemental figure 1). Therefore, for these biomarkers both the sex and age-specific (ie, below or above age 60) lower and upper quartiles were defined as high risk, while only one quartile for the others (upper or lower, in accordance with the existing literature) (see online supplemental table 1).

Associations between all-cause mortality and dichotomised biomarkers levels (low/high risk), system-specific AL scores and total AL index, were modelled with Cox proportional-hazard models. Here, we present two models: Model 1, where HRs are adjusted for sex and age; Model 2, where results are further adjusted for BMI, prevalent diseases and smoking status. HRs for the individual biomarkers (table 1) and for system-specific AL scores (table 2) are mutually adjusted. Proportional hazards assumptions in the above models have been tested using Schoenfeld residuals. Numbers below 5 are not reported. In addition, we report HRs for a one-point increase in the AL index.

Data management, statistical analyses and plots were done in R V.4.0.3,³² with packages splines,³² survival,³³ tidyverse,³⁴ ggrepel³⁵ and ggpubr.³⁶

RESULTS

The LOFUS database used for this study included 13725 persons, of whom 53% were women and 47% men. The median follow-up time was 2.6 years (IQR 1.5) and the median age was 57.6 in women and 59.9 in men. One-fourth of the participants were obese, and one-fifth were current smokers. Presence of cardiovascular disease at the time of LOFUS participation was reported by 28%, diabetes by 5% and cancer by 4%. On the value of total AL index, participants were divided approximately into tertiles; 32% low, 40% mid and 38% high. During the

 Table 1
 Multivariate Cox proportional hazard regression of all-cause mortality for Lolland-Falster Health Study participants by individual biomarkers

Variable	Non exposed	Exposed	HR (95% CI) Model 1*	HR (95% CI) Model 2†
HDL cholesterol, mmol/L	High	Low	1.22 (0.88 to 1.69)	1.24 (0.89 to 1.73)
LDL cholesterol, mmol/L	Mid	High and low	1.22 (0.91 to 1.62)	1.13 (0.85 to 1.51)
Triglycerides, mmol/L	Low	High	0.93 (0.66 to 1.32)	0.94 (0.67 to 1.33)
Albumin, g/L	High	Low	1.55 (1.17 to 2.07)	1.54 (1.16 to 2.06)
CRP, mg/L	Low	High	1.42 (1.05 to 1.92)	1.41 (1.04 to 1.91)
HbA1c, mmol/mol	Low	High	1.25 (0.93 to 1.68)	1.24 (0.90 to 1.71)
Systolic blood pressure, mm Hg	Mid	High and low	1.20 (0.90 to 1.61)	1.17 (0.88 to 1.57)
Diastolic blood pressure, mm Hg	Mid	High and low	1.31 (0.98 to 1.76)	1.28 (0.95 to 1.72)
Pulse rate, PM	High	Low	1.34 (0.99 to 1.81)	1.23 (0.91 to 1.66)
Waist-hip ratio	Low	High	1.02 (0.74 to 1.41)	1.08 (0.76 to 1.52)

*Adjusted for age and sex.

†Additionally adjusted for body mass index, reported diseases and smoking status.

CRP, C-reactive protein; HbA1c, glycated haemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PM, per minute.

 Table 2
 Multivariate Cox proportional hazard regression of all-cause mortality for Lolland-Falster Health Study participants by allostatic load index

Variable	Reference	Level	HR (95% CI) Model 1*	HR (95% CI) Model 2†
Allostatic load index	Low	Mid	1.39 (0.94 to 2.06)	1.33 (0.89 to 1.98)
		High	2.45 (1.68 to 3.59)	2.37 (1.58 to 3.54)
Continuous allostatic load measure			1.23 (1.14 to 1.32)	1.22 (1.13 to 1.32)
Inflammatory system score	Low	Mid	1.03 (0.74 to 1.44)	1.02 (0.73 to 1.42)
		High	2.39 (1.69 to 3.38)	2.38 (1.67 to 3.39)
Metabolic system score	Low	Mid	1.19 (0.76 to 1.86)	1.18 (0.75 to 1.85)
		High	1.54 (1.02 to 2.33)	1.54 (1.00 to 2.38)
Cardiovascular system score	Low	Mid	1.73 (1.08 to 1.78)	1.65 (1.02 to 2.65)
		High	2.06 (1.31 to 3.24)	1.89 (1.20 to 2.99)

*Adjusted for age and sex.

†Additionally adjusted for body mass index, reported diseases and smoking status.

follow-up period, 198 participants died; of these 39% were women and 61% men (table 3).

The multivariate Cox proportional hazard regression for individual biomarker and all-cause mortality, adjusted for sex and age and additionally for BMI, reported diseases and smoking, are listed in table 1. For all biomarkers, apart from triglycerides, a high-risk value was associated with an increased mortality level. However, only the HRs for low albumin and high CRP were statistically significantly elevated; HR 1.54 (95% CI: 1.16 to 2.06) and 1.41 (95% CI: 1.04 to 1.91), respectively.

The HR for all-cause mortality increased with increasing level of the AL from low as the reference over mid to high, table 2 and figure 1. For the IS AL score, the HR was 1.02 (95% CI: 0.73 to 1.42) for mid AL, and 2.38 (95% CI: 1.67 to 3.39) for high AL. For the MS AL score, the HRs were 1.18 (95% CI: 0.75 to 1.85) and 1.54 (95% CI: 1.00 to 2.38), respectively. For the CVS AL score, the HRs were 1.65 (95% CI: 1.02 to 2.65) and 1.89 (95% CI: 1.20 to 2.99), respectively. The gradient for the total AL index was a HR of 1.33 (95% CI: 0.89 to 1.98) for mid AL, and 2.37 (95% CI: 1.58 to 3.54) for high AL. HRs for one unit increase in AL (continuous AL) was 1.23 (1.14–1.32) when adjusted for age and sex, and 1.22 (1.13–1.32), when additionally adjusted for BMI, reported diseases and smoking status.

DISCUSSION

In this population-based study from a rural-provincial area of Denmark, we followed the adult population up for a median period of 2.6 years. High levels of individual biomarkers were overall associated with increased mortality, but most of them at a modest level of 20%–30%, and statistically significantly elevated for only CRP and albumin. High levels of physiological system-specific AL scores were associated with increased mortality at the level of 50%–140%; statistically significantly for the IS and CVS, and at borderline of significance for the MS.

The composite measure of total AL index was a strong predictor of all-cause mortality. Persons with a high versus low total AL index had about 2.5 times the mortality. The total AL index was thus a better predictor of all-cause mortality than individual biomarkers and the MS and CVS AL scores, a pattern consistent with previous studies.¹⁶¹⁸³⁷

The most comprehensive studies on AL and mortality all used data from the National Health and Nutrition Examination Survey (NHANES). Borrell *et al*⁸⁸ examined 12-year mortality by using data from 13715 adults aged 25+ years of whom 2491 had died. They calculated AL based on nine biomarkers; albumin, CRP, total cholesterol, HDL-c, HbA1c, WHR, SBP, DBP and PR. Using a clinical cut-off AL score, they found that, compared with persons with an AL score of ≤1, those with AL scores of 2 and 3+ had adjusted HRs of 1.40 (95% CI: 1.11 to 1.76) and 1.88 (95% CI: 1.56 to 2.26), respectively.

Levine and Crimmins³⁹ examined 10-year all-cause and disease-specific mortality. In total, 15042 persons were eligible, but biomarker data were available for only 9942 adults aged 30+, of whom 1076 had died. They included data on albumin, CRP, WHR, total cholesterol, HDL-c, HbA1c, PR, SBP and DBP. For each of the nine biomarkers, a person was classified as high or low based on clinical cut-off points, and the AL score was the number of biomarkers classified as high. In addition, an expanded AL score included 5 additional biomarkers defined by quintiles; and a continuous AL score used a continuous z-score measure for all 14 biomarkers. For the first AL score, a HR of 2.75 (p<0.001) was found for allcause mortality when persons with the highest quintile of AL were compared with those with the lowest. Somewhat stronger gradients were found for the expanded; 3.62 (p<0.0001) and continuous; 6.97 (p<0.0001), ALs.

Howard and Sparks⁴⁰ studied 11733 participants from NHANES. Imputation was used to estimate missing values. Their AL measure was based on DBP, SBP, PR, total cholesterol, HDL-c, triglycerides, HbA1c, BMI,

Table 3 Lolland-Falster Health Study (LOFUS). Baseline characteristics of study population and deaths in follow-up period, n(%). For definition of cut-off values, see online supplemental table 1


Characteristics	Females	Males	Total	Female death	Male death	Total death
Population	7270 (53)	6455 (47)	13725 (100)	78 (39)	120 (61)	198 (100)
⁻ ollow-up time, median (IQR)	2.6 (1.6)	2.7 (1.5)	2.6 (1.5)	2.0 (1.6)	1.9 (1.8)	1.9 (1.8)
Vledian age (IQR)	57.6 (21.9)	59.9 (21.6)	58.7 (22.0)	70.5 (16.4)	74.0 (15.2)	72.8 (16.2)
BMI, kg/m ²						
Underweight	134 (1.8)	42 (0.7)	176 (1.3)	5 (6.4)	Not reported	6 (3.0)
Normal weight	3038 (41.8)	1862 (28.8)	4900 (35.7)	29 (37.2)	40 (33.3)	69 (34.8)
Overweight	2335 (32.1)	2940 (45.5)	5275 (38.4)	26 (33.3)	52 (43.3)	78 (39.4)
Obese	1763 (24.3)	1611 (25.0)	3374 (24.6)	18 (23.1)	27 (22.5)	45 (22.7)
Smoking						
Never	3586 (49.3)	2737 (42.4)	6323 (46.1)	21 (26.9)	24 (20.0)	45 (22.7)
Former	2342 (32.2)	2425 (37.6)	4767 (34.7)	32 (41.0)	70 (58.3)	102 (51.5)
Current	1342 (18.5)	1293 (20.0)	2635 (19.2)	25 (32.1)	26 (21.7)	51 (25.8)
Chronic conditions						
Cardiovascular disease reported	1828 (25.1)	1999 (31.0)	3827 (27.9)	42 (53.8)	60 (50.0)	102 (51.5)
Diabetes reported	264 (3.6)	440 (6.8)	704 (5.1)	9 (11.5)	15 (12.5)	24 (12.1)
Cancer reported	245 (3.4)	275 (4.3)	520 (3.8)	13 (16.7)	24 (20.0)	37 (18.7)
Cardiovascular system						
Systolic blood pressure						
Low risk	3548 (48.8)	3165 (49.0)	6713 (48.9)	32 (41.0)	52 (43.3)	84 (42.4)
High risk	3722 (51.2)	3290 (51.0)	7012 (51.1)	46 (59.0)	68 (56.7)	114 (57.6)
Diastolic blood pressure						
Low risk	3426 (47.1)	3164 (49.0)	6590 (48.0)	26 (33.3)	52 (43.3)	78 (39.4)
High risk	3844 (52.9)	3291 (51.0)	7135 (52.0)	52 (66.7)	68 (56.7)	120 (60.6)
Pulse rate						
Low risk	5366 (73.8)	4721 (73.1)	10087 (73.5)	50 (64.1)	81 (67.5)	131 (66.2)
High risk	1904 (26.2)	1734 (26.9)	3638 (26.5)	28 (35.9)	39 (32.5)	67 (33.8)
AL cardiovascular system score						
Low	1815 (25.0)	1506 (23.3)	3321 (24.2)	7 (9.0)	16 (13.3)	23 (11.6)
Mid	2117 (29.1)	2154 (33.4)	4271 (31.1)	27 (34.6)	43 (35.8)	70 (35.4)
High	3338 (45.9)	2795 (43.3)	6133 (44.7)	44 (56.4)	61 (50.8)	105 (53.0)
Metabolic system	. ,	. ,	. ,			. ,
HDL-c						
Low risk	4934 (67.9)	4706 (72.9)	9640 (70.2)	46 (59.0)	85 (70.8)	131 (66.2)
High risk	2336 (32.1)	1749 (27.1)	4085 (29.8)	32 (41.0)	35 (29.2)	67 (33.8)
Triglycerides	. ,	. ,	. /	. ,	. ,	, ,
Low risk	5299 (72.9)	4761 (73.8)	10060 (73.3)	50 (64.1)	95 (79.2)	145 (73.2)
High risk	1971 (27.1)	1694 (26.2)	3665 (26.7)	28 (35.9)	25 (20.8)	53 (26.8)
HbA1c	· /	· · /		. ,	. /	\ -/
Low risk	5156 (70.9)	4438 (68.8)	9594 (69.9)	46 (59.0)	69 (57.5)	115 (58.1)
High risk	2114 (29.1)	2017 (31.2)	4131 (30.1)	32 (41.0)	51 (42.5)	83 (41.9)
Waist-hip ratio	()	(__)				(•)
Low risk	5452 (75.0)	4831 (74.8)	10283 (74.9)	57 (73.1)	85 (70.8)	142 (71.7)
High risk	1818 (25.0)	1624 (25.2)	3442 (25.1)	21 (26.9)	35 (29.2)	56 (28.3)
LDL-c	(2010))	2	(_0.0)		00 (20.0)
	3459 (47.6)	2989 (46.3)	6448 (47.0)	31 (39.7)	51 (42.5)	82 (41.4)


Characteristics	Females	Males	Total	Female death	Male death	Total death
High risk	3811 (52.4)	3466 (53.7)	7277 (53.0)	47 (60.3)	69 (57.5)	116 (58.6)
AL metabolic system score						
Low	1401 (19.3)	1249 (19.3)	2650 (19.3)	11 (14.1)	18 (15.0)	29 (14.6)
Mid	2413 (33.2)	2135 (33.1)	4548 (33.1)	18 (23.1)	37 (30.8)	55 (27.8)
High	3456 (47.5)	3071 (47.6)	6527 (47.6)	49 (62.8)	65 (54.2)	114 (57.6)
Inflammation system						
CRP						
Low risk	5451 (75.0)	4837 (74.9)	10288 (75.0)	51 (65.4)	73 (60.8)	124 (62.6)
High risk	1819 (25.0)	1618 (25.1)	3437 (25.0)	27 (34.6)	47 (39.2)	74 (37.4)
Albumin						
Low risk	4953 (68.1)	4655 (72.1)	9608 (70.0)	49 (62.8)	54 (45.0)	103 (52.0)
High risk	2317 (31.9)	1800 (27.9)	4117 (30.0)	29 (37.2)	66 (55.0)	95 (48.0)
AL inflammation system score						
Low	4027 (55.4)	3692 (57.2)	7719 (56.2)	41 (52.6)	42 (35.0)	83 (41.9)
Mid	2350 (32.3)	2108 (32.7)	4458 (32.5)	18 (23.1)	43 (35.8)	61 (30.8)
High	893 (12.3)	655 (10.1)	1548 (11.3)	19 (24.4)	35 (29.2)	54 (27.3)
Total AL index						
Low	2306 (31.7)	2112 (32.7)	4418 (32.2)	14 (17.9)	24 (20.0)	38 (19.2)
Mid	2882 (39.6)	2599 (40.3)	5481 (39.9)	26 (33.3)	45 (37.5)	71 (35.9)
High	2082 (28.6)	1744 (27.0)	3826 (27.9)	38 (48.7)	51 (42.5)	89 (44.9)

AL, allostatic load; BMI, body mass index; CRP, C-reactive protein; HbA1c, glycated haemoglobin A1c; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol.

albumin and CRP. They found that a one-unit increase in AL represented a 7% increase in risk of death when adjusted for age, sex, ethnicity, socioeconomic status and health behaviour.

The National Child Development Study was followed-up for deaths from birth in 1958 to 1 December 2013, that is, to the age of 55 years.¹⁸ AL based on 10 biomarkers was calculated and divided into three levels. All-cause mortality for persons with mid or high AL was compared with that of persons with low AL, and adjusted for early life, childhood, young and adulthood confounders. The





HR of death was 1.71 (95% CI: 1.07 to 2.72) for persons with mid AL, and 2.57 (95% CI: 1.59 to 4.15) for those with high AL. The association between AL and all-cause mortality was stronger than the associations between of the individual 10 biomarkers and all-cause mortality.

The NHANES studies vary in number of participants included in the studies, in length of follow-up for mortality, in biomarkers included, in the definition of AL and in methods used for AL calculation. Nevertheless, all the studies indicated that all-cause mortality increased with increasing AL. The study by Borell *et al*⁸⁸ is the one methodologically most similar to our study and the gradient of 1.88 (95% CI: 1.56 to 2.26) is compatible with the 1 of 2.37 (95% CI: 1.58 to 3.54) found in our study, and so is the gradient of 2.57 (95% CI: 1.59 to 4.15) found in the National Child Development Study.

For individual biomarkers in our study, HRs were highest for CRP and albumin. CRP is the prototypical acute-phase response protein that increases during systemic inflammation,⁴¹ while albumin is a major component of plasma protein, required for transportation and to maintain oncotic pressure, acid–base function, microvascular permeability and to prevent platelet aggregation.⁴² Inflammation increases capillary permeability and thereby escape of serum albumin, leading to expansion of interstitial space and increasing the distribution volume of albumin causing lower serum albumin concentrations. High level of CRP and low level of albumin have thus previously been linked with a variety of health outcomes including morbidity and mortality.⁷⁸⁴³

We found a U-shaped association between LDL-c and mortality. Elevated LDL-c is a well-established risk factor of atherosclerosis and cardiovascular disease, and the general perception is that high level of LDL-c is associated with an increased risk of morbidity and mortality.4445 Nevertheless, studies on the association between LDL-c levels and mortality have provided conflicting results. Some studies found increasing level of LDL-c to be associated with lower mortality,⁵⁴⁶ and some studies found no association.^{45 47 48} However, most studies were conducted in elderly people often with an intake of lipid-lowering agents. A more recent study in young Koreans found an association between low level of LDL-c and an increased risk of cancer, cardiovascular and all-cause mortality.⁴⁹ These findings were supported by a Chinese study of participants aged 40+ years.⁵⁰ A recent Danish study among 108243 individuals aged 20-100 years found the lowest all-cause mortality at an LDL-c concentration of 3.6 mmol/L (140 mg/dL), and higher mortality at both lower and higher levels.⁵¹ Our findings for LDL-c were thus in accordance with these recent observations. Seplaki et al suggested that both high and low ends of the risk continuum for the construct of AL could be more informative than simply using high-risk quartiles. They assigned a value of '1' for values above the 75th percentile and below the 25th percentile of the distribution, and a value of '0' for intermediate values.⁵²

We found both higher and lower levels of DBP to be associated with an increased mortality, and a similar tendency was indicated for SBP. The association between lower BP and mortality is still of discussion.^{53–55} Most studies have found this association among elderly people and linked it to chronic disease, for example, cardiovascular disease (cardiac failure or ischaemic heart disease), cancer, poor functional status or frailty. Low BP has also been associated with poor function and low quality of life,^{56 57} but in previous studies only the highest quartile or the clinical cut-off value have been used as predictor of all-cause mortality.

Several methods have been used to define an AL composite index, including the count-based, canonical correlation, z-score and grade of membership method.^{58 59} The most commonly used method is the count-based method, where a summary index is calculated by summing the number of biomarkers falling within the high-risk category, either defined by the percentile (ie, upper or lower 25th percentile of the sample's distribution) or by the clinical cut-off value. In our analysis with the two-tail cut-off points, we found HRs for LDL-c of 1.13 (95% CI: 0.85 to 1.51); for SBP of 1.17 (95% CI: 0.88 to 1.57; and for DBP of 1.28 (95% CI: 0.95 to 1.72). If we have used instead the single high-risk quartile cut-off point, we would have found HRs for LDL-c of 0.71 (95% CI: 0.49 to 1.03); for SBP of 0.96 (95% CI: 0.68 to 1.35) vs), and for DBP of 1.24 (95% CI: 0.86 to 1.81). The two-tail cut-off

points thus provided a better identification of persons with high mortality than the one-tail cut-off points.

The issue of whether a clinical or sample-based cut-off criteria should be used is still of discussion,¹⁷ however, studies comparing distinct measurement approaches have found only modest differences in their predictive utility.^{15 60 61}

Strengths and limitations

The strengths of our study included the size of the cohort in terms of the large number of individuals recruited from a general adult population, and the complete follow-up for death by linkage with the Danish Civil Registration System.

Our study also had some limitations. First, the choice of biomarkers used to construct the AL index. The AL theory emphasises the importance of measuring dysregulation across different physiological systems, including biomarkers from the neuroendocrine, CVS, MS and IS.¹³ The neuroendocrine system (stress response) is believed to play a key role in allostasis and subsequent AL, as a series of physiological changes takes place before initial stress responses occur (such as rapid increases in blood sugar and BP that supply the body with additional energy). However, biomarkers from the neuroendocrine system are difficult to measure, as repeated measurements over 1-2 days are recommended. These requirements cannot be fulfilled in population studies, where participants are examined only once, and biomarkers from the neuroendocrine system were therefore not available for our study.

Second, the initial stress responses are followed by secondary outcomes from the MS, IS and CVS, and these markers were all available in our data. Nevertheless, greater sensitivity could have been achieved by studying the dynamic changes over time in these markers to fully capture the flexibility of stress response mechanisms across the lifespan.

Finally, differences across studies in construction of AL indices could influence the comparison of results. We used the shape of the association between level of a given biomarker and all-cause mortality as the basis for the categorisation of the biomarker into low and high values. One can argue therefore that our analysis was circular in the way that we used outcome on the dependent variable to categorise levels of the independent variable. We believe that this was justifiable in the context here where the purpose was to optimise the predictive power of the AL index. However, validation in other data sets are needed before our approach can be recommended for research in general and for eventual clinical use.

Conclusion

Our findings demonstrated that an optimally constructed AL index was a strong predictor of all-cause mortality. This supported the conceptual validity of AL as an effective marker of the cumulative physiological burden on the body. These findings can contribute to the evidence for the use of an AL index as a basis for targeted efforts to bring down continued stress exposures, and in this way prevent the potential detrimental effect of these exposures on health. Our findings on the U-shaped association with LDL-c, DBP and SBP and all-cause mortality suggested that AL measures incorporating risks at both the low and the high end of biomarkers may yield the best prediction of all-cause mortality.

Twitter Randi Jepsen @RandiJepsen

Acknowledgements We thank inhabitants of Lolland-Falster for their participation in LOFUS and for their permission to use their data for research purposes. The Lolland-Falster Health Study (LOFUS), Nykøbing Falster Hospital, Denmark, is a collaboration between Region Zealand, Nykøbing Falster Hospital, and Lolland and Guldborgsund Municipalities. The authors are grateful to LOFUS for making the LOFUS research data available. However, LOFUS bears no responsibility for the analysis or the interpretation conducted within this study.

Contributors All authors contributed significantly to the study. RJ provided the LOFUS data. NEB-R, EL and GN designed the study, interpreted the data and drafted the manuscript. GN performed the statistical analysis. CE, CC, RJ, KR and SEB contributed to the interpretation and writing of the manuscript. All authors critically revised and approved the final manuscript. EL is the guarantor.

Funding (1) Region Zealand/University of Copenhagen, (2) Nykøbing Falster Hospital, (3) Professor grants for Elsebeth Lynge and (4) Danish Health Insurance Foundation 19-B-0188. The funding bodies had no role in the design of the study, neither in the collection, analysis and interpretation of data, nor in the writing of the manuscript.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval Approval was granted by Region Zealand's Ethical Committee on Health Research (Reg: SJ-421). All data storage and management were approved by the Regional Data Protection Agency of Zealand (REG-024-2019 and REG-24-2015). LOFUS is registered in ClinicalTrials.gov (NCT02482896). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. Data from the study can be made available via Region Sjaelland following the Danish Data Protection Regulation.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Neda Esmailzadeh Bruun-Rasmussen http://orcid.org/0000-0003-4002-9062 Christina Ellervik http://orcid.org/0000-0002-3088-4375

REFERENCES

 Hulka BS. Overview of biological markers. In: Hulka BS, Griffith JD, Wilcosky TC, eds. *Biological markers in epidemiology*. New York: Oxford University Press, 1990: 3–15.

- Naylor S. Biomarkers: current perspectives and future prospects. Expert Rev Mol Diagn 2003;3:525–9.
- 3 Peto MV, De la Guardia C, Winslow K, et al. MortalityPredictors.org: a manually-curated database of published biomarkers of human allcause mortality. Aging 2017;9:1916–25.
- 4 Liu J, Zeng FF, Liu ZM. Effects of blood triglycerides on cardiovascular and all-cause mortality: a systematic review and meta-analysis of 61 prospective studies. *Lipids Health Dis*;2013:159.
- 5 Schupf N, Costa R, Luchsinger J, *et al.* Relationship between plasma lipids and all-cause mortality in nondemented elderly. *J Am Geriatr* Soc 2005;53:219–26.
- 6 Zhong G-C, Huang S-Q, Peng Y, *et al*. Hdl-C is associated with mortality from all causes, cardiovascular disease and cancer in a J-shaped dose-response fashion: a pooled analysis of 37 prospective cohort studies. *Eur J Prev Cardiol* 2020;27:1187–203.
- 7 Levitt D, Levitt M. Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements. *Int J Gen Med*;9:229–55.
- 8 Li Y, Zhong X, Cheng G, et al. Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: a meta-analysis. *Atherosclerosis* 2017;259:75–82.
- 9 Sakurai M, Saitoh S, Miura K, et al. Hba1C and the risks for all-cause and cardiovascular mortality in the general Japanese population: nippon DATA90. Diabetes Care 2013;36:3759–65.
- 10 Ravnskov U, Diamond DM, Hama R, et al. Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review. BMJ Open 2016;6:e010401.
- 11 Doran B, Zhu W, Muennig P. Gender differences in cardiovascular mortality by C-reactive protein level in the United States: evidence from the National health and nutrition examination survey III. Am Heart J 2013;166:45–51.
- 12 McEwen BS, Gianaros PJ. Central role of the brain in stress and adaptation: links to socioeconomic status, health, and disease. Ann N Y Acad Sci 2010;1186:190–222.
- 13 Seeman TE, Singer BH, Rowe JW. Price of adaptation-allostatic load and its health consequences MacArthur studies of successful aging. *Arch Intern Med* 19991997;157:2259–68.
- 14 Hastings WJ, Almeida DM, Shalev I. Conceptual and analytical overlap between allostatic load and systemic biological aging measures: analyses from the National survey of midlife development in the United States. J Gerontol A Biol Sci Med Sci 2021:glab187.
- 15 Gruenewald TL, Karlamangla AS, Hu P, et al. History of socioeconomic disadvantage and allostatic load in later life. Soc Sci Med 2012;74:75–83.
- 16 Duong MT, Bingham BA, Aldana PC, et al. Variation in the calculation of allostatic load score: 21 examples from NHANES. J Racial Ethn Health Disparities 2017;4:455–61.
- 17 Mauss D, Li J, Schmidt B, et al. Measuring allostatic load in the workforce: a systematic review. Ind Health 2015;53:5–20.
- 18 Castagné R, Garès V, Karimi M, et al. Allostatic load and subsequent all-cause mortality: which biological markers drive the relationship? findings from a UK birth cohort. Eur J Epidemiol 2018;33:441–58.
- 19 Howard DC. Signal detection to measure allostatic load. *J Nurs* Scholarsh 2021;53:351–7.
- 20 Jepsen R, Egholm CL, Brodersen J, et al. Lolland-Falster health study: study protocol for a household-based prospective cohort study. Scand J Public Health 2020;48:382–90.
- 21 Statistics Denmark. Available: http://www.statistikbanken.dk/10015 [Accessed 27 Oct 2020].
- 22 Blaakilde AL, Hansen BH, Olesen LS. Health Profile 2017 for Region Zealand and municipalities - "How are you?" (in Danish). Sorø, Danmark: Region Zealand, 2018.
- 23 Jepsen R, Wingstrand A, Ábild SL. Socio-Economic determinants of participation in the Lolland-Falster health study. *J Public Health* 2019;17:1403494818799613.
- 24 Warnick GR, Knopp RH, Fitzpatrick V, et al. Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. *Clin Chem* 1990;36:15–19.
- 25 Zhang T, Yan LL, Chen H-S, et al. Association between allostatic load and mortality among Chinese older adults: the Chinese longitudinal health and longevity study. *BMJ Open* 2021;11:e045369.
- 26 Kallen V, Tahir M, Bedard A, et al. Aging and allostasis: using Bayesian network analytics to explore and evaluate allostatic markers in the context of aging. *Diagnostics* 2022;11:157.
- 27 Williams B, Mancia G, Spiering W. 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of cardiology and the European Society of hypertension: the task force

6

for the management of arterial hypertension of the European Society of cardiology and the European Society of hypertension. *J Hypertens* 2018;3736:2261953–2041.

- 28 World Health Organization. Waist circumference and waist-hip ratio report of a who expert consultation. Geneva: World Health Organization, 2008. http://www.whqlibdoc.who.int.ep.fjernadgang. kb.dk/publications/2011/9789241501491_eng.pdf.
- 29 Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Atherosclerosis 2007;194:1–45.
- 30 Dansk Selskab for Almen Medicin, Danish Association for General Practice, Clinical Guideline. Type 2 Diabetes - Et metabolisk syndrom. Copenhagen, Denmark. Available: http://vejledninger. dsam.dk/type2
- 31 Rustad P, Felding P, Franzson L, et al. The Nordic reference interval project 2000: recommended reference intervals for 25 common biochemical properties. Scand J Clin Lab Invest 2004;64:271–84.
- 32 R Core Team. R: a language and environment for statistical computing. R foundation for statistical computing, Vienna, Austria, 2020. Available: https://www.R-project.org/
- 33 Therneau T. A package for survival analysis in R_. R package version 3.2-7, 2020. Available: https://CRAN.R-project.org/package= survival>
- 34 Wickham H, Averick M, Bryan J, et al. Welcome to the Tidyverse. J Open Source Softw 2019;4:1686.
- 35 Slowikowski K. ggrepel: Automatically Position Non-Overlapping Text Labels with 'ggplot2'. R package version 0.9.1, 2021. Available: https://CRAN.R-project.org/package=ggrepel
- 36 Kassambara A. ggpubr: 'ggplot2' Based Publication Ready Plots. R package version 0.4.0., 2020. Available: https://CRAN.R-project.org/ package=ggpubr
- 37 Robertson T, Beveridge G, Bromley C. Allostatic load as a predictor of all-cause and cause-specific mortality in the general population: evidence from the Scottish health survey. *PLoS One* 2017;12:e0183297.
- 38 Borrell LN, Dallo FJ, Nguyen N. Racial/Ethnic disparities in all-cause mortality in U.S. adults: the effect of allostatic load. *Public Health Rep* 2010;125:810–6.
- 39 Levine ME, Crimmins EM. A comparison of methods for assessing mortality risk. *Am J Hum Biol* 2014;26:768–76.
- 40 Howard JT, Sparks PJ. The effects of allostatic load on racial/ethnic mortality differences in the United States. *Popul Res Policy Rev* 2016;35:421–43.
- 41 Marnell L, Mold C, Du Clos TW. C-Reactive protein: ligands, receptors and role in inflammation. *Clin Immunol* 2005;117:104–11.
- 42 Doweiko JP, Nompleggi DJ. The role of albumin in human physiology and pathophysiology, part III: albumin and disease states. JPEN J Parenter Enteral Nutr 1991;15:476–83.
- 43 Soeters PB, Wolfe RR, Shenkin A. Hypoalbuminemia: pathogenesis and clinical significance. JPEN J Parenter Enteral Nutr 2019;43:181–93.
- 44 Mortensen MB, Nordestgaard BG. Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years:

a contemporary primary prevention cohort. *Lancet* 2020;396:1644–52.

- 45 Kronmal RA, Cain KC, Ye Z, *et al*. Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data. *Arch Intern Med* 1993;153:1065–73.
- 46 Bathum L, Depont Christensen R, Engers Pedersen L, et al. Association of lipoprotein levels with mortality in subjects aged 50 + without previous diabetes or cardiovascular disease: a populationbased register study. Scand J Prim Health Care 2013;31:172–80.
- 47 Psaty BM, Anderson M, Kronmal RA, et al. The association between lipid levels and the risks of incident myocardial infarction, stroke, and total mortality: the cardiovascular health study. J Am Geriatr Soc 2004;52:1639–47.
- 48 Fried LP, Kronmal RA, Newman AB, *et al*. Risk factors for 5-year mortality in older adults: the cardiovascular health study. *JAMA* 1998;279:585–92.
- 49 Sung KC, Huh JH, Ryu S. Low levels of low-density lipoprotein cholesterol and mortality outcomes in Non-Statin users. *J Clin Med*;8:1571.
- 50 JM L, MY W, Yang ZM. Low LDL-C levels are associated with risk of mortality in a Chinese cohort study. *Endocrine* 2021.
- 51 Johannesen CDL, Langsted A, Mortensen MB. Association between low density lipoprotein and all cause and cause specific mortality in Denmark: prospective cohort study. *BMJ* 2021;372:n422.
- 52 Seplaki CL, Goldman N, Glei D, et al. A comparative analysis of measurement approaches for physiological dysregulation in an older population. *Exp Gerontol* 2005;40:438–49.
- 53 Franklin SS, Gokhale SS, Chow VH, et al. Does low diastolic blood pressure contribute to the risk of recurrent hypertensive cardiovascular disease events? the Framingham heart study. *Hypertension* 2015;65:299–305.
- 54 Kim JK, Crimmins EM, Pressure B. Blood pressure and mortality: joint effect of blood pressure measures. J Clin Cardiol Cardiovasc Ther 2020;2:1009.
- 55 Dorresteijn JAN, van der Graaf Y, Spiering W, *et al.* Relation between blood pressure and vascular events and mortality in patients with manifest vascular disease: J-curve revisited. *Hypertension* 2012;59:14–21.
- 56 Poortvliet RKE, de Ruijter W, de Craen AJM, et al. Blood pressure trends and mortality: the Leiden 85-plus study. J Hypertens 2013;31:63–70.
- 57 Sabayan B, Oleksik AM, Maier AB, et al. High blood pressure and resilience to physical and cognitive decline in the oldest old: the Leiden 85-plus study. J Am Geriatr Soc 2012;60:2014–9.
- 58 Juster R-P, McEwen BS, Lupien SJ. Allostatic load biomarkers of chronic stress and impact on health and cognition. *Neurosci Biobehav Rev* 2010;35:2–16.
- 59 Li Y, Rosemberg M-AS, Dalton VK, et al. Exploring the optimal allostatic load scoring method in women of reproductive age. J Adv Nurs 2019;75:2548–58.
- 60 McEwen BS, Stellar E. Stress and the individual. mechanisms leading to disease. *Arch Intern Med* 1993;153:2093–101.
- 61 McEwen BS, Stress MBS. Stress, adaptation, and disease. allostasis and allostatic load. *Ann N Y Acad Sci* 1998;840:33–44.